Skip to content
Disability, Medical Health Aged Care

CPA Funds Breakthrough Blood Test that Can Identify Underlying Cause of Brain Injury in Newborns

Cerebral Palsy Alliance 3 mins read

SYDNEY, March 21, 2024 – A new blood test that can pinpoint the root cause of brain injury in newborns could revolutionise treatment, Chair of Cerebral Palsy Research at Cerebral Palsy Alliance (CPA), Professor Nadia Badawi said.

The study, funded by CPA and carried out by researchers at Imperial College London, examined babies experiencing brain injury due to hypoxia, a lack of oxygen to the brain. By analysing patterns of gene expression in the blood, researchers were able to determine the cause of the injury and predict the likelihood of the newborn responding to cooling therapy, the "gold standard" treatment for brain injury in infants.
Professor Nadia Badawi said the findings could be "revolutionary".

"The study investigated the differences in gene expression in newborns with hypoxic-ischaemic encephalopathy (HIE) - some from High Income Countries (Italy), and others from low- and middle-income countries (LMIC) in South Asia. Newborn encephalopathy is much more prevalent in South Asia than for Europe and Australia, and previous work has demonstrated that gold standard therapy - cooling - is ineffective and potentially dangerous in the LMIC settings. This study helps explain why and provides insights that will allow more effective treatment.

"The investigators found clear differences in gene expression between those infants born in HIC and those from LMIC. The differences in gene expression between the two groups suggest that the causal pathways to HIE may differ in the two  socio-economic settings, and subsequently, the capacity to derive benefit from cooling is altered. "
Professor Badawi said the study provided valuable insights into the complex nature of brain injury in newborns and by better understanding the underlying mechanisms, clinicians could make more informed treatment decisions and improve outcomes for babies.

Globally, HIE is a leading cause of death and disability among babies born at full term, affecting around three million babies every year. Following oxygen deprivation, brain injury can develop over hours to months and affect different regions of the brain, resulting in a variety of potential neurodisabilities such as cerebral palsy or epilepsy.

Lead investigator, Professor Sudhin Thayyil from the Department of Brain Sciences at Imperial College London said that the study showed that although cases of brain injury in newborns may appear similar, the underlying causes can be quite distinct . 
This breakthrough blood test offers a non-invasive and efficient method for diagnosing brain injury in newborns, allowing for timely interventions and personalised treatment.

 

About Cerebral Palsy Alliance: 

Cerebral Palsy Alliance is a ground-breaking, global centre of expertise for cerebral palsy research, advocacy, intervention, and assistive technology innovation. As the world’s largest private funder of cerebral palsy research, we bring together a powerful alliance of great minds.  Our research-informed interventions are world-class, our unique accelerator program is unlocking the potential of technology to drive greater inclusion for people with disability, and our voice is a powerhouse for bringing together communities and countries in effecting change.

 

CONTACT:

Cerebral Palsy Alliance Media and Thought Leadership Manager, Martin Zavan

0424 295 422

[email protected] 


Key Facts:

* Cerebral Palsy affects 1 in 1000 children in Australia. Thanks to the work of organsations like CPA, that rate has been reduced by 40 per cent over the last 20 years.

* Cerebral Palsy is the most common physical disability in children in Australia.

* Babies under six months old can now be diagnosed with cerebral pasly at one of CPA's Early Diagnosis Centres.


About us:

About Cerebral Palsy Alliance: 

Cerebral Palsy Alliance (CPA) is a global centre of expertise and a leading not-for-profit organisation dedicated to providing support, services, and advocacy for individuals with cerebral palsy and their families. With a focus on innovation and excellence, CPA strives to improve the lives of individuals with CP through research, therapy, education, and community support. 


Contact details:

Media and Thought Leadership Manager, Martin Zavan

0424 295 422

[email protected]

Media

More from this category

  • Medical Health Aged Care, Women
  • 19/12/2025
  • 16:00
Breast Cancer Network Australia

Affordable access to life extending drug for people with incurable breast cancer.

Key Facts: Tucatinib, a breast cancer drug, will be listed on PBS, saving patients over $4,500 per month The drug is specifically for HER2-positive metastatic breast cancer patients, particularly those with brain metastases Interviews: Larissa King - woman living with breast cancer that has spread to the brain Vicki Durston. BCNA Director Policy, Advocacy and Support Services. People with breast cancer that has spread to the brain will save more than $4500 a month when Tucatinib is listed on the Pharmaceutical Benefits Scheme in the coming weeks. Breast Cancer Network Australia (BCNA) welcomes today’s decision by the Pharmaceutical Benefits Advisory…

  • Medical Health Aged Care
  • 19/12/2025
  • 09:05
Royal Australian College of GPs

RACGP celebrates WA excellence in general practice at awards

The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct Associate Professor Frank R Jones, recognising his 45 years of service to general practice, including 40 years at Murray Medical Centre in Mandurah. Professor Jones has worked across rural, procedural, and community settings and held numerous leadership roles within the RACGP, including President, Vice President,…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.